![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED
K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED
June 16, 2006
Analysts at Deutsche Bank Securities maintain their "hold" rating on K-V Pharmaceutical. The target price has been reduced from $26 to $20.
Newratings
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct